<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03373383</url>
  </required_header>
  <id_info>
    <org_study_id>EP0091</org_study_id>
    <secondary_id>2017-003200-48</secondary_id>
    <nct_id>NCT03373383</nct_id>
  </id_info>
  <brief_title>Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy</brief_title>
  <acronym>ARISE</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Dose Finding Study to Evaluate the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects With Drug-Resistant Epilepsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Biopharma S.P.R.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to characterize the dose-response relationship with respect to&#xD;
      efficacy of Padsevonil administered concomitantly with up to 3 anti-epileptic drugs (AEDs)&#xD;
      for treatment of observable focal-onset seizures in subjects with drug-resistant epilepsy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 12, 2018</start_date>
  <completion_date type="Actual">January 30, 2020</completion_date>
  <primary_completion_date type="Actual">January 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Log-transformed Observable Focal Onset Seizure Frequency From Baseline Over the 12 Week Maintenance Period</measure>
    <time_frame>From Baseline over the 12 Week Maintenance Period</time_frame>
    <description>During the study, participants kept diaries to record daily seizure activity. Seizure frequency refers to 28-day adjusted frequency. Seizure frequency was based on investigator assessment of participants' reports of daily seizure type and frequency. Observable focal-onset seizures refer to Type IA1, IB, and IC (ILAE Classification of Epileptic Seizures, 1981). Based on ANCOVA on change in log-transformed, 28-day adjusted seizure frequency from Baseline with treatment group as the main factor, Baseline log-transformed seizure frequency as a continuous covariate, Baseline SV2A use (yes or no) and Region (Europe, Non-Europe) as categorical factors.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) Reported by the Subject and/or Caregiver or Observed by the Investigator During the Entire Study</measure>
    <time_frame>From Baseline until Safety Follow-Up (up to Week 23)</time_frame>
    <description>An Adverse Event is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) Leading to Study Withdrawal</measure>
    <time_frame>From Baseline until Safety Follow-Up (up to Week 23)</time_frame>
    <description>An Adverse Event is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Treatment-Emergent Serious Adverse Events (SAEs) During the Entire Study</measure>
    <time_frame>From Baseline until Safety Follow-Up (up to Week 23)</time_frame>
    <description>A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose:&#xD;
Results in death&#xD;
Is life-threatening&#xD;
Requires in patient hospitalization or prolongation of existing hospitalization&#xD;
Is a congenital anomaly or birth defect&#xD;
Is an infection that requires treatment parenteral antibiotics&#xD;
Other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>75 % Responder Rate Over the 12 Week Maintenance Period</measure>
    <time_frame>End of Maintenance Period (Week 16) following 3 Weeks of titration and 1 Week stabilization</time_frame>
    <description>The 75% responder rate, where a responder is a participant experiencing a ≥75% reduction in observable focal-onset seizure frequency from Baseline, over the 12-Week Maintenance Period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>50 % Responder Rate Over the 12 Week Maintenance Period</measure>
    <time_frame>End of Maintenance Period (Week 16) following 3 Weeks of titration and 1 Week stabilization</time_frame>
    <description>The 50% responder rate, where a responder was a participant experiencing a ≥50% reduction in observable focal-onset seizure frequency from Baseline, over the 12-Week Maintenance Period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Observable Focal-onset Seizure Frequency From Baseline Over the 12 Week Maintenance Period</measure>
    <time_frame>End of Maintenance Period (Week 16) following 3 Weeks of titration and 1 Week stabilization</time_frame>
    <description>During the study, participants kept diaries to record daily seizure activity. The percentage of participants who experienced a 50 % or greater reduction in seizure frequency per 28 days relative to Baseline (responders) was assessed.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">411</enrollment>
  <condition>Drug-resistant Epilepsy</condition>
  <condition>Focal-Onset Seizures</condition>
  <arm_group>
    <arm_group_label>Padsevonil dosing regimen 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomized to receive a combination of tablets of Padsevonil and Placebo (as appropriate) to maintain the blinding.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Padsevonil dosing regimen 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomized to receive a combination of tablets of Padsevonil and Placebo (as appropriate) to maintain the blinding.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Padsevonil dosing regimen 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomized to receive a combination of tablets of Padsevonil and Placebo (as appropriate) to maintain the blinding.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Padsevonil dosing regimen 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomized to receive a combination of tablets of Padsevonil and Placebo (as appropriate) to maintain the blinding.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects randomized to the placebo group will receive a combination of several Placebo tablets to maintain the blinding.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Padsevonil</intervention_name>
    <description>Padsevonil in different dosages.</description>
    <arm_group_label>Padsevonil dosing regimen 1</arm_group_label>
    <arm_group_label>Padsevonil dosing regimen 2</arm_group_label>
    <arm_group_label>Padsevonil dosing regimen 3</arm_group_label>
    <arm_group_label>Padsevonil dosing regimen 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be provided matching Padsevonil.</description>
    <arm_group_label>Padsevonil dosing regimen 1</arm_group_label>
    <arm_group_label>Padsevonil dosing regimen 2</arm_group_label>
    <arm_group_label>Padsevonil dosing regimen 3</arm_group_label>
    <arm_group_label>Padsevonil dosing regimen 4</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of focal epilepsy per 1989 International League Against Epilepsy (ILAE)&#xD;
             criteria at least 3 years before study entry&#xD;
&#xD;
          -  Subject has failed to achieve seizure control with 4 tolerated and appropriately&#xD;
             chosen prior antiepileptic drugs (AED), including past and ongoing treatment, that&#xD;
             were individually optimized for adequate dose and duration. Prior discontinued AED&#xD;
             treatment would need to be assessed by the Investigator considering the patient&#xD;
             medical records and patient and/or caregiver interview. 'Prior AED' is defined as all&#xD;
             past and ongoing AED treatments with a start date before the Screening Visit (Visit 1)&#xD;
&#xD;
          -  Average of &gt;= 4 spontaneous and observable focal seizures (type IA1 (i.e. focal&#xD;
             aware), IB (i.e. focal impaired awareness), IC (i.e. focal to bilateral tonic-clonic))&#xD;
             per month&#xD;
&#xD;
          -  Current treatment with an individually optimized and stable dose of at least 1 and up&#xD;
             to 3 AEDs for the 8 weeks prior to the Screening Visit with or without additional&#xD;
             Vagus Nerve Stimulation (VNS) or other neurostimulation treatments&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has a history of or signs of generalized or combined generalized and focal&#xD;
             epilepsy&#xD;
&#xD;
          -  Cluster seizures which are uncountable in the previous 8 weeks before study entry and&#xD;
             during 4 weeks prospective baseline&#xD;
&#xD;
          -  Current treatment with carbamazepine, phenytoin, primidone, phenobarbital&#xD;
&#xD;
          -  Current treatment/ use of (non-AED) prescription, nonprescription, dietary (eg,&#xD;
             grapefruit or passion fruit), or herbal products that are potent inducers or&#xD;
             inhibitors of the CYP3A4 or 2C19 pathway for 2 weeks (or 5 half-lives, whichever is&#xD;
             longer) prior to the Baseline Visit&#xD;
&#xD;
          -  Subjects taking sensitive substrates of CYP2C19 for 2 weeks (or 5 half-lives,&#xD;
             whichever is longer) prior to the Baseline Visit&#xD;
&#xD;
          -  Subject has been taking vigabatrin less than 2 years at study entry&#xD;
&#xD;
          -  Subject has been taking felbamate for less than 12 months&#xD;
&#xD;
          -  Subject taking retigabine for less than 4 years&#xD;
&#xD;
          -  Current treatment with benzodiazepines (i.e. GABA-A-ergic drugs like zolpidem,&#xD;
             zaleplon, or zopiclone, excluding GABA-A-ergic AEDs) &lt;3 times per week for emergencies&#xD;
&#xD;
          -  Subject has a current medical condition that occurred within the last 12 months which,&#xD;
             in the opinion of the investigator, could compromise his/her safety or ability to&#xD;
             participate in this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Cares</last_name>
    <role>Study Director</role>
    <affiliation>001 844 599 2273 (UCB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ep0091 839</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 810</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 815</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 801</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 845</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 809</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 823</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 825</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 820</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 873</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 803</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 832</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 822</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 818</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 817</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 806</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 827</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016-48</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 800</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 802</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 838</name>
      <address>
        <city>Cordova</city>
        <state>Tennessee</state>
        <zip>38018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 835</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 805</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 844</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78758</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 836</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 830</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-91</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 824</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78681</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 870</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 855</name>
      <address>
        <city>Box Hill</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 857</name>
      <address>
        <city>Clayton</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 850</name>
      <address>
        <city>Fitzroy</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 859</name>
      <address>
        <city>Herston</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 852</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 853</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 856</name>
      <address>
        <city>Randwick</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 854</name>
      <address>
        <city>Westmead</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 102</name>
      <address>
        <city>Brugge</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 101</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 105</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 100</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 150</name>
      <address>
        <city>Blagoevgrad</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 151</name>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 153</name>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 152</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 154</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 155</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 200</name>
      <address>
        <city>Greenfield Park</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 205</name>
      <address>
        <city>London</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 201</name>
      <address>
        <city>Montréal</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 254</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 255</name>
      <address>
        <city>Ostrava-Poruba</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 252</name>
      <address>
        <city>Praha 4</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 250</name>
      <address>
        <city>Praha 5</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 253</name>
      <address>
        <city>Praha 8</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 251</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 307</name>
      <address>
        <city>Clermont-Ferrand Cedex 1</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 309</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 300</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 302</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 305</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 303</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 306</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 361</name>
      <address>
        <city>Bad Neustadt An Der Saale</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 365</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 362</name>
      <address>
        <city>Bernau</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 363</name>
      <address>
        <city>Bielefeld</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 358</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 350</name>
      <address>
        <city>Frankfurt am main</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 360</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 364</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 368</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 366</name>
      <address>
        <city>Kork</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 357</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 353</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 354</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 351</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 356</name>
      <address>
        <city>Osnabrück</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 367</name>
      <address>
        <city>Ravensburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 301</name>
      <address>
        <city>Strausberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 352</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 400</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 403</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 402</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 462</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 450</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 461</name>
      <address>
        <city>Foggia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 452</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 459</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 453</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 458</name>
      <address>
        <city>Pozzilli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 454</name>
      <address>
        <city>Reggio Calabria</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 455</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 457</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 460</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 501</name>
      <address>
        <city>Asaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 511</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 505</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 513</name>
      <address>
        <city>Hōfu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 507</name>
      <address>
        <city>Itami</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 503</name>
      <address>
        <city>Kodaira</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 514</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 512</name>
      <address>
        <city>Nagakute</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 510</name>
      <address>
        <city>Niigata</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 515</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 509</name>
      <address>
        <city>Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 703</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 701</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 702</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 553</name>
      <address>
        <city>Culiacán</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 552</name>
      <address>
        <city>Mexico Distrito Federal</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 601</name>
      <address>
        <city>Gdańsk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 607</name>
      <address>
        <city>Grodzisk Mazowiecki</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 605</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 608</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 603</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 604</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 606</name>
      <address>
        <city>Nowa Sól</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 600</name>
      <address>
        <city>Poznań</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 609</name>
      <address>
        <city>Poznań</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 602</name>
      <address>
        <city>Świdnik</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 952</name>
      <address>
        <city>Santa Maria Da Feira</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 004</name>
      <address>
        <city>Bardejov</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 001</name>
      <address>
        <city>Hlohovec</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 662</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 651</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 652</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 658</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 664</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 668</name>
      <address>
        <city>Bilbao</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 666</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 650</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 656</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 660</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 661</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 659</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 663</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 665</name>
      <address>
        <city>Terrassa</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 657</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 667</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 653</name>
      <address>
        <city>Valladolid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 904</name>
      <address>
        <city>Eskişehir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 900</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 901</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 752</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 751</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 756</name>
      <address>
        <city>Inverness</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 757</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 750</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0091 753</name>
      <address>
        <city>Swansea</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 7, 2017</study_first_submitted>
  <study_first_submitted_qc>December 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2017</study_first_posted>
  <results_first_submitted>January 28, 2021</results_first_submitted>
  <results_first_submitted_qc>March 16, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 9, 2021</results_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epilepsy</keyword>
  <keyword>Padsevonil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Seizures</mesh_term>
    <mesh_term>Drug Resistant Epilepsy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.</ipd_access_criteria>
    <ipd_url>http://www.Vivli.org</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 12, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/83/NCT03373383/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 12, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/83/NCT03373383/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study started to enroll patients in February 2018 and concluded in January 2020.</recruitment_details>
      <pre_assignment_details>The study included: a 4-week Baseline Period, a 16-week Treatment Period, a 4-week Taper Period (for participants who discontinued or choose not to enroll in the open-label extension study) and a Safety Follow-up Period. Participants continuing to the OLE study had a 3-week Conversion Period.&#xD;
Participant Flow refers to the Randomized Set.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants randomized to the placebo group received 5-6 placebo tablets to maintain the blinding up to week 19.</description>
        </group>
        <group group_id="P2">
          <title>Padsevonil 50mg BID</title>
          <description>Participants were randomized to receive a combination of tablets of padsevonil 50 milligrams (mg) and placebo (as appropriate) to maintain the blinding, twice daily (bid) up to week 19</description>
        </group>
        <group group_id="P3">
          <title>Padsevonil 100mg BID</title>
          <description>Participants were randomized to receive a combination of tablets of padsevonil 100 mg and placebo (as appropriate) to maintain the blinding, bid up to week 19.</description>
        </group>
        <group group_id="P4">
          <title>Padsevonil 200mg BID</title>
          <description>Participants were randomized to receive a combination of tablets of padsevonil 200 mg and placebo (as appropriate) to maintain the blinding, bid up to week 19.</description>
        </group>
        <group group_id="P5">
          <title>Padsevonil 400mg BID</title>
          <description>Participants were randomized to receive a combination of tablets of padsevonil 400 mg and placebo (as appropriate) to maintain the blinding, bid up to week 19.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period: Wk0-16</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
                <participants group_id="P2" count="81"/>
                <participants group_id="P3" count="83"/>
                <participants group_id="P4" count="82"/>
                <participants group_id="P5" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Titration and Stabilization</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
                <participants group_id="P2" count="72"/>
                <participants group_id="P3" count="71"/>
                <participants group_id="P4" count="68"/>
                <participants group_id="P5" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Maintenance Period</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="66"/>
                <participants group_id="P3" count="68"/>
                <participants group_id="P4" count="61"/>
                <participants group_id="P5" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Had Taper and Safety Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="18"/>
                <participants group_id="P5" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="66"/>
                <participants group_id="P3" count="68"/>
                <participants group_id="P4" count="61"/>
                <participants group_id="P5" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="21"/>
                <participants group_id="P5" count="24"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>As advised by the sponsor</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>By opinion of investigator</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Post-Treatment Period: Wk16-23</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="66"/>
                <participants group_id="P3" count="68"/>
                <participants group_id="P4" count="61"/>
                <participants group_id="P5" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Started Conversion Period</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="64"/>
                <participants group_id="P3" count="66"/>
                <participants group_id="P4" count="55"/>
                <participants group_id="P5" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Conversion Period</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="64"/>
                <participants group_id="P3" count="66"/>
                <participants group_id="P4" count="55"/>
                <participants group_id="P5" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Had Taper and Safety Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Enrolled in EP0093</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="63"/>
                <participants group_id="P3" count="65"/>
                <participants group_id="P4" count="55"/>
                <participants group_id="P5" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="66"/>
                <participants group_id="P3" count="68"/>
                <participants group_id="P4" count="61"/>
                <participants group_id="P5" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Participant decided not to roll over</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline characteristics refer to the Randomized Set (RS) consisting of all participants randomized into the study.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants randomized to the placebo group received 5-6 placebo tablets to maintain the blinding up to week 19.</description>
        </group>
        <group group_id="B2">
          <title>Padsevonil 50mg BID</title>
          <description>Participants were randomized to receive a combination of tablets of padsevonil 50 milligrams (mg) and placebo (as appropriate) to maintain the blinding, twice daily (bid) up to week 19</description>
        </group>
        <group group_id="B3">
          <title>Padsevonil 100mg BID</title>
          <description>Participants were randomized to receive a combination of tablets of padsevonil 100 mg and placebo (as appropriate) to maintain the blinding, bid up to week 19.</description>
        </group>
        <group group_id="B4">
          <title>Padsevonil 200mg BID</title>
          <description>Participants were randomized to receive a combination of tablets of padsevonil 200 mg and placebo (as appropriate) to maintain the blinding, bid up to week 19.</description>
        </group>
        <group group_id="B5">
          <title>Padsevonil 400mg BID</title>
          <description>Participants were randomized to receive a combination of tablets of padsevonil 400 mg and placebo (as appropriate) to maintain the blinding, bid up to week 19.</description>
        </group>
        <group group_id="B6">
          <title>Total Title</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="83"/>
            <count group_id="B2" value="81"/>
            <count group_id="B3" value="83"/>
            <count group_id="B4" value="82"/>
            <count group_id="B5" value="82"/>
            <count group_id="B6" value="411"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="80"/>
                    <measurement group_id="B4" value="79"/>
                    <measurement group_id="B5" value="80"/>
                    <measurement group_id="B6" value="397"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.0" spread="12.9"/>
                    <measurement group_id="B2" value="42.5" spread="11.6"/>
                    <measurement group_id="B3" value="36.9" spread="13.1"/>
                    <measurement group_id="B4" value="40.9" spread="12.0"/>
                    <measurement group_id="B5" value="38.8" spread="12.1"/>
                    <measurement group_id="B6" value="39.8" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="51"/>
                    <measurement group_id="B5" value="43"/>
                    <measurement group_id="B6" value="235"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="39"/>
                    <measurement group_id="B6" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="73"/>
                    <measurement group_id="B4" value="69"/>
                    <measurement group_id="B5" value="71"/>
                    <measurement group_id="B6" value="351"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other/mixed</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Log-transformed Observable Focal Onset Seizure Frequency From Baseline Over the 12 Week Maintenance Period</title>
        <description>During the study, participants kept diaries to record daily seizure activity. Seizure frequency refers to 28-day adjusted frequency. Seizure frequency was based on investigator assessment of participants' reports of daily seizure type and frequency. Observable focal-onset seizures refer to Type IA1, IB, and IC (ILAE Classification of Epileptic Seizures, 1981). Based on ANCOVA on change in log-transformed, 28-day adjusted seizure frequency from Baseline with treatment group as the main factor, Baseline log-transformed seizure frequency as a continuous covariate, Baseline SV2A use (yes or no) and Region (Europe, Non-Europe) as categorical factors.</description>
        <time_frame>From Baseline over the 12 Week Maintenance Period</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all study participants in the RS who were administered at least 1 dose or a partial dose of IMP and had Baseline and at least 1 post-Baseline seizure frequency data during the 16-week Treatment Period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (FAS)</title>
            <description>Participants randomized to the placebo group received 5-6 placebo tablets to maintain the blinding up to week 19. Participants formed the Full Analysis Set (FAS).</description>
          </group>
          <group group_id="O2">
            <title>Padsevonil 50mg BID (FAS)</title>
            <description>Participants were randomized to receive a combination of tablets of padsevonil 50 mg and placebo (as appropriate) to maintain the blinding, bid up to week 19. Participants formed the FAS.</description>
          </group>
          <group group_id="O3">
            <title>Padsevonil 100mg BID (FAS)</title>
            <description>Participants were randomized to receive a combination of tablets of padsevonil 100 mg and placebo (as appropriate) to maintain the blinding, bid up to week 19. Participants formed the FAS.</description>
          </group>
          <group group_id="O4">
            <title>Padsevonil 200mg BID (FAS)</title>
            <description>Participants were randomized to receive a combination of tablets of padsevonil 200 mg and placebo (as appropriate) to maintain the blinding, bid up to week 19. Participants formed the FAS.</description>
          </group>
          <group group_id="O5">
            <title>Padsevonil 400mg BID (FAS)</title>
            <description>Participants were randomized to receive a combination of tablets of padsevonil 400 mg and placebo (as appropriate) to maintain the blinding, bid up to week 19. Participants formed the FAS.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Log-transformed Observable Focal Onset Seizure Frequency From Baseline Over the 12 Week Maintenance Period</title>
          <description>During the study, participants kept diaries to record daily seizure activity. Seizure frequency refers to 28-day adjusted frequency. Seizure frequency was based on investigator assessment of participants' reports of daily seizure type and frequency. Observable focal-onset seizures refer to Type IA1, IB, and IC (ILAE Classification of Epileptic Seizures, 1981). Based on ANCOVA on change in log-transformed, 28-day adjusted seizure frequency from Baseline with treatment group as the main factor, Baseline log-transformed seizure frequency as a continuous covariate, Baseline SV2A use (yes or no) and Region (Europe, Non-Europe) as categorical factors.</description>
          <population>The Full Analysis Set (FAS) consisted of all study participants in the RS who were administered at least 1 dose or a partial dose of IMP and had Baseline and at least 1 post-Baseline seizure frequency data during the 16-week Treatment Period.</population>
          <units>loge seizures per 28 days</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="81"/>
                <count group_id="O5" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27585" lower_limit="-0.44311" upper_limit="-0.10858"/>
                    <measurement group_id="O2" value="-0.46424" lower_limit="-0.63276" upper_limit="-0.29573"/>
                    <measurement group_id="O3" value="-0.48804" lower_limit="-0.65436" upper_limit="-0.32172"/>
                    <measurement group_id="O4" value="-0.48960" lower_limit="-0.65734" upper_limit="-0.32187"/>
                    <measurement group_id="O5" value="-0.40831" lower_limit="-0.57485" upper_limit="-0.24177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percent reduction over placebo was calculated as 100*(1-exp(diff)), where diff was the model estimate of the log ratio between each PSL group and placebo group.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.102</p_value>
            <p_value_desc>Adjusted p-values were from the Hochberg step-up procedure within SAS® Proc Multtest to control Type I error.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Percent reduction</param_type>
            <param_value>17.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.8</ci_lower_limit>
            <ci_upper_limit>33.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Percent reduction over placebo was calculated as 100*(1-exp(diff)), where diff was the model estimate of the log ratio between each PSL group and placebo group.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.064</p_value>
            <p_value_desc>Adjusted p-values were from the Hochberg step-up procedure within SAS® Proc Multtest to control Type I error.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Percent reduction</param_type>
            <param_value>19.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.2</ci_lower_limit>
            <ci_upper_limit>35.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Percent reduction over placebo was calculated as 100*(1-exp(diff)), where diff was the model estimate of the log ratio between each PSL group and placebo group.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.063</p_value>
            <p_value_desc>Adjusted p-values were from the Hochberg step-up procedure within SAS® Proc Multtest to control Type I error.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Percent reduction</param_type>
            <param_value>19.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.2</ci_lower_limit>
            <ci_upper_limit>35.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Percent reduction over placebo was calculated as 100*(1-exp[diff]), where diff was the model estimate of the log ratio between each PSL group and placebo group.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.248</p_value>
            <p_value_desc>Adjusted p-values were from the Hochberg step-up procedure within SAS® Proc Multtest to control Type I error.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Percent reduction</param_type>
            <param_value>12.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.7</ci_lower_limit>
            <ci_upper_limit>30.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>75 % Responder Rate Over the 12 Week Maintenance Period</title>
        <description>The 75% responder rate, where a responder is a participant experiencing a ≥75% reduction in observable focal-onset seizure frequency from Baseline, over the 12-Week Maintenance Period.</description>
        <time_frame>End of Maintenance Period (Week 16) following 3 Weeks of titration and 1 Week stabilization</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all study participants in the RS who were administered at least 1 dose or a partial dose of IMP and had Baseline and at least 1 post-Baseline seizure frequency data during the 16-week Treatment Period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (FAS)</title>
            <description>Participants randomized to the placebo group received 5-6 placebo tablets to maintain the blinding up to week 19. Participants formed the Full Analysis Set (FAS).</description>
          </group>
          <group group_id="O2">
            <title>Padsevonil 50mg BID (FAS)</title>
            <description>Participants were randomized to receive a combination of tablets of padsevonil 50 mg and placebo (as appropriate) to maintain the blinding, bid up to week 19. Participants formed the FAS.</description>
          </group>
          <group group_id="O3">
            <title>Padsevonil 100mg BID (FAS)</title>
            <description>Participants were randomized to receive a combination of tablets of padsevonil 100 mg and placebo (as appropriate) to maintain the blinding, bid up to week 19. Participants formed the FAS.</description>
          </group>
          <group group_id="O4">
            <title>Padsevonil 200mg BID (FAS)</title>
            <description>Participants were randomized to receive a combination of tablets of padsevonil 200 mg and placebo (as appropriate) to maintain the blinding, bid up to week 19. Participants formed the FAS.</description>
          </group>
          <group group_id="O5">
            <title>Padsevonil 400mg BID (FAS)</title>
            <description>Participants were randomized to receive a combination of tablets of padsevonil 400 mg and placebo (as appropriate) to maintain the blinding, bid up to week 19. Participants formed the FAS.</description>
          </group>
        </group_list>
        <measure>
          <title>75 % Responder Rate Over the 12 Week Maintenance Period</title>
          <description>The 75% responder rate, where a responder is a participant experiencing a ≥75% reduction in observable focal-onset seizure frequency from Baseline, over the 12-Week Maintenance Period.</description>
          <population>The Full Analysis Set (FAS) consisted of all study participants in the RS who were administered at least 1 dose or a partial dose of IMP and had Baseline and at least 1 post-Baseline seizure frequency data during the 16-week Treatment Period.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="81"/>
                <count group_id="O5" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2"/>
                    <measurement group_id="O2" value="13.8"/>
                    <measurement group_id="O3" value="12.2"/>
                    <measurement group_id="O4" value="11.1"/>
                    <measurement group_id="O5" value="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PSL dose/Placebo was calculated using logistic regression with categorical factors for treatment group, Region (Europe, Non-Europe), Baseline SV2A use (0, 1) and log-transformed Baseline seizure frequency as a continuous covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.081</p_value>
            <p_value_desc>Nominal p-values were not adjusted for multiplicity.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>8.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PSL dose/Placebo was calculated using logistic regression with categorical factors for treatment group, Region (Europe, Non-Europe), Baseline SV2A use (0, 1) and log-transformed Baseline seizure frequency as a continuous covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.137</p_value>
            <p_value_desc>Nominal p-values were not adjusted for multiplicity.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>7.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PSL dose/Placebo was calculated using logistic regression with categorical factors for treatment group, Region (Europe, Non-Europe), Baseline SV2A use (0, 1) and log-transformed Baseline seizure frequency as a continuous covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.192</p_value>
            <p_value_desc>Nominal p-values were not adjusted for multiplicity.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>6.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>PSL dose/Placebo was calculated using logistic regression with categorical factors for treatment group, Region (Europe, Non-Europe), Baseline SV2A use (0, 1) and log-transformed Baseline seizure frequency as a continuous covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.041</p_value>
            <p_value_desc>Nominal p-values were not adjusted for multiplicity.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.05</ci_lower_limit>
            <ci_upper_limit>9.42</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) Reported by the Subject and/or Caregiver or Observed by the Investigator During the Entire Study</title>
        <description>An Adverse Event is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment.</description>
        <time_frame>From Baseline until Safety Follow-Up (up to Week 23)</time_frame>
        <population>The Safety Set consisted of all study participants who were administered at least 1 dose or a partial dose of IMP.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (SS)</title>
            <description>Participants randomized to the placebo group received 5-6 placebo tablets to maintain the blinding up to week 19. Participants formed the Safety Set (SS).</description>
          </group>
          <group group_id="O2">
            <title>Padsevonil 50mg BID (SS)</title>
            <description>Participants were randomized to receive a combination of tablets of padsevonil 50 mg and Placebo (as appropriate) to maintain the blinding, bid up to week 19. Participants formed the SS.</description>
          </group>
          <group group_id="O3">
            <title>Padsevonil 100mg BID (SS)</title>
            <description>Participants were randomized to receive a combination of tablets of padsevonil 100 mg and placebo (as appropriate) to maintain the blinding, bid up to week 19. Participants formed the SS.</description>
          </group>
          <group group_id="O4">
            <title>Padsevonil 200mg BID (SS)</title>
            <description>Participants were randomized to receive a combination of tablets of padsevonil 200 mg and placebo (as appropriate) to maintain the blinding, bid up to week 19. Participants formed the SS.</description>
          </group>
          <group group_id="O5">
            <title>Padsevonil 400mg BID (SS)</title>
            <description>Participants were randomized to receive tablets of padsevonil 400 mg and placebo (as appropriate) to maintain the blinding, bid up to week 19. Participants formed the SS.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) Reported by the Subject and/or Caregiver or Observed by the Investigator During the Entire Study</title>
          <description>An Adverse Event is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment.</description>
          <population>The Safety Set consisted of all study participants who were administered at least 1 dose or a partial dose of IMP.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="83"/>
                <count group_id="O4" value="82"/>
                <count group_id="O5" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.3"/>
                    <measurement group_id="O2" value="84.0"/>
                    <measurement group_id="O3" value="80.7"/>
                    <measurement group_id="O4" value="75.6"/>
                    <measurement group_id="O5" value="92.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) Leading to Study Withdrawal</title>
        <description>An Adverse Event is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment.</description>
        <time_frame>From Baseline until Safety Follow-Up (up to Week 23)</time_frame>
        <population>The Safety Set consisted of all study participants who were administered at least 1 dose or a partial dose of IMP.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (SS)</title>
            <description>Participants randomized to the placebo group received 5-6 placebo tablets to maintain the blinding up to week 19. Participants formed the Safety Set (SS).</description>
          </group>
          <group group_id="O2">
            <title>Padsevonil 50mg BID (SS)</title>
            <description>Participants were randomized to receive a combination of tablets of padsevonil 50 mg and Placebo (as appropriate) to maintain the blinding, bid up to week 19. Participants formed the SS.</description>
          </group>
          <group group_id="O3">
            <title>Padsevonil 100mg BID (SS)</title>
            <description>Participants were randomized to receive a combination of tablets of padsevonil 100 mg and placebo (as appropriate) to maintain the blinding, bid up to week 19. Participants formed the SS.</description>
          </group>
          <group group_id="O4">
            <title>Padsevonil 200mg BID (SS)</title>
            <description>Participants were randomized to receive a combination of tablets of padsevonil 200 mg and placebo (as appropriate) to maintain the blinding, bid up to week 19. Participants formed the SS.</description>
          </group>
          <group group_id="O5">
            <title>Padsevonil 400mg BID (SS)</title>
            <description>Participants were randomized to receive tablets of padsevonil 400 mg and placebo (as appropriate) to maintain the blinding, bid up to week 19. Participants formed the SS.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) Leading to Study Withdrawal</title>
          <description>An Adverse Event is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment.</description>
          <population>The Safety Set consisted of all study participants who were administered at least 1 dose or a partial dose of IMP.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="83"/>
                <count group_id="O4" value="82"/>
                <count group_id="O5" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4"/>
                    <measurement group_id="O2" value="7.4"/>
                    <measurement group_id="O3" value="12.0"/>
                    <measurement group_id="O4" value="18.3"/>
                    <measurement group_id="O5" value="25.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Treatment-Emergent Serious Adverse Events (SAEs) During the Entire Study</title>
        <description>A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose:&#xD;
Results in death&#xD;
Is life-threatening&#xD;
Requires in patient hospitalization or prolongation of existing hospitalization&#xD;
Is a congenital anomaly or birth defect&#xD;
Is an infection that requires treatment parenteral antibiotics&#xD;
Other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above.</description>
        <time_frame>From Baseline until Safety Follow-Up (up to Week 23)</time_frame>
        <population>The Safety Set consisted of all study participants who were administered at least 1 dose or a partial dose of IMP.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (SS)</title>
            <description>Participants randomized to the placebo group received 5-6 placebo tablets to maintain the blinding up to week 19. Participants formed the Safety Set (SS).</description>
          </group>
          <group group_id="O2">
            <title>Padsevonil 50mg BID (SS)</title>
            <description>Participants were randomized to receive a combination of tablets of padsevonil 50 mg and Placebo (as appropriate) to maintain the blinding, bid up to week 19. Participants formed the SS.</description>
          </group>
          <group group_id="O3">
            <title>Padsevonil 100mg BID (SS)</title>
            <description>Participants were randomized to receive a combination of tablets of padsevonil 100 mg and placebo (as appropriate) to maintain the blinding, bid up to week 19. Participants formed the SS.</description>
          </group>
          <group group_id="O4">
            <title>Padsevonil 200mg BID (SS)</title>
            <description>Participants were randomized to receive a combination of tablets of padsevonil 200 mg and placebo (as appropriate) to maintain the blinding, bid up to week 19. Participants formed the SS.</description>
          </group>
          <group group_id="O5">
            <title>Padsevonil 400mg BID (SS)</title>
            <description>Participants were randomized to receive tablets of padsevonil 400 mg and placebo (as appropriate) to maintain the blinding, bid up to week 19. Participants formed the SS.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Treatment-Emergent Serious Adverse Events (SAEs) During the Entire Study</title>
          <description>A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose:&#xD;
Results in death&#xD;
Is life-threatening&#xD;
Requires in patient hospitalization or prolongation of existing hospitalization&#xD;
Is a congenital anomaly or birth defect&#xD;
Is an infection that requires treatment parenteral antibiotics&#xD;
Other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above.</description>
          <population>The Safety Set consisted of all study participants who were administered at least 1 dose or a partial dose of IMP.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="83"/>
                <count group_id="O4" value="82"/>
                <count group_id="O5" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8"/>
                    <measurement group_id="O2" value="7.4"/>
                    <measurement group_id="O3" value="4.8"/>
                    <measurement group_id="O4" value="6.1"/>
                    <measurement group_id="O5" value="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>50 % Responder Rate Over the 12 Week Maintenance Period</title>
        <description>The 50% responder rate, where a responder was a participant experiencing a ≥50% reduction in observable focal-onset seizure frequency from Baseline, over the 12-Week Maintenance Period.</description>
        <time_frame>End of Maintenance Period (Week 16) following 3 Weeks of titration and 1 Week stabilization</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all study participants in the RS who were administered at least 1 dose or a partial dose of IMP and had Baseline and at least 1 post-Baseline seizure frequency data during the 16-week Treatment Period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (FAS)</title>
            <description>Participants randomized to the placebo group received 5-6 placebo tablets to maintain the blinding up to week 19. Participants formed the Full Analysis Set (FAS).</description>
          </group>
          <group group_id="O2">
            <title>Padsevonil 50mg BID (FAS)</title>
            <description>Participants were randomized to receive a combination of tablets of padsevonil 50 mg and placebo (as appropriate) to maintain the blinding, bid up to week 19. Participants formed the FAS.</description>
          </group>
          <group group_id="O3">
            <title>Padsevonil 100mg BID (FAS)</title>
            <description>Participants were randomized to receive a combination of tablets of padsevonil 100 mg and placebo (as appropriate) to maintain the blinding, bid up to week 19. Participants formed the FAS.</description>
          </group>
          <group group_id="O4">
            <title>Padsevonil 200mg BID (FAS)</title>
            <description>Participants were randomized to receive a combination of tablets of padsevonil 200 mg and placebo (as appropriate) to maintain the blinding, bid up to week 19. Participants formed the FAS.</description>
          </group>
          <group group_id="O5">
            <title>Padsevonil 400mg BID (FAS)</title>
            <description>Participants were randomized to receive a combination of tablets of padsevonil 400 mg and placebo (as appropriate) to maintain the blinding, bid up to week 19. Participants formed the FAS.</description>
          </group>
        </group_list>
        <measure>
          <title>50 % Responder Rate Over the 12 Week Maintenance Period</title>
          <description>The 50% responder rate, where a responder was a participant experiencing a ≥50% reduction in observable focal-onset seizure frequency from Baseline, over the 12-Week Maintenance Period.</description>
          <population>The Full Analysis Set (FAS) consisted of all study participants in the RS who were administered at least 1 dose or a partial dose of IMP and had Baseline and at least 1 post-Baseline seizure frequency data during the 16-week Treatment Period.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="81"/>
                <count group_id="O5" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.0"/>
                    <measurement group_id="O2" value="33.8"/>
                    <measurement group_id="O3" value="31.7"/>
                    <measurement group_id="O4" value="25.9"/>
                    <measurement group_id="O5" value="32.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PSL dose/placebo calculated using logistic regression with categorical factors for treatment group (each PSL dose group referenced to the placebo group), region (Europe, Non-Europe), Baseline SV2A use (0, 1) and log-transformed Baseline seizure frequency as a continuous covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.045</p_value>
            <p_value_desc>Nominal p-values were not adjusted for multiplicity.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.02</ci_lower_limit>
            <ci_upper_limit>4.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PSL dose/placebo calculated using logistic regression with categorical factors for treatment group (each PSL dose group referenced to the placebo group), region (Europe, Non-Europe), Baseline SV2A use (0, 1) and log-transformed Baseline seizure frequency as a continuous covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.079</p_value>
            <p_value_desc>Nominal p-values were not adjusted for multiplicity.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>3.93</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PSL dose/placebo calculated using logistic regression with categorical factors for treatment group (each PSL dose group referenced to the placebo group), region (Europe, Non-Europe), Baseline SV2A use (0, 1) and log-transformed Baseline seizure frequency as a continuous covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.338</p_value>
            <p_value_desc>Nominal p-values were not adjusted for multiplicity.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>3.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>PSL dose/Placebo calculated using logistic regression with categorical factors for treatment group, Region (Europe, Non-Europe), Baseline SV2A use (0, 1) and log-transformed Baseline seizure frequency as a continuous covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.087</p_value>
            <p_value_desc>Nominal p-values were not adjusted for multiplicity.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>3.87</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Observable Focal-onset Seizure Frequency From Baseline Over the 12 Week Maintenance Period</title>
        <description>During the study, participants kept diaries to record daily seizure activity. The percentage of participants who experienced a 50 % or greater reduction in seizure frequency per 28 days relative to Baseline (responders) was assessed.</description>
        <time_frame>End of Maintenance Period (Week 16) following 3 Weeks of titration and 1 Week stabilization</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all study participants in the RS who were administered at least 1 dose or a partial dose of IMP and had Baseline and at least 1 post-Baseline seizure frequency data during the 16-week Treatment Period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (FAS)</title>
            <description>Participants randomized to the placebo group received 5-6 placebo tablets to maintain the blinding up to week 19. Participants formed the Full Analysis Set (FAS).</description>
          </group>
          <group group_id="O2">
            <title>Padsevonil 50mg BID (FAS)</title>
            <description>Participants were randomized to receive a combination of tablets of padsevonil 50 mg and placebo (as appropriate) to maintain the blinding, bid up to week 19. Participants formed the FAS.</description>
          </group>
          <group group_id="O3">
            <title>Padsevonil 100mg BID (FAS)</title>
            <description>Participants were randomized to receive a combination of tablets of padsevonil 100 mg and placebo (as appropriate) to maintain the blinding, bid up to week 19. Participants formed the FAS.</description>
          </group>
          <group group_id="O4">
            <title>Padsevonil 200mg BID (FAS)</title>
            <description>Participants were randomized to receive a combination of tablets of padsevonil 200 mg and placebo (as appropriate) to maintain the blinding, bid up to week 19. Participants formed the FAS.</description>
          </group>
          <group group_id="O5">
            <title>Padsevonil 400mg BID (FAS)</title>
            <description>Participants were randomized to receive a combination of tablets of padsevonil 400 mg and placebo (as appropriate) to maintain the blinding, bid up to week 19. Participants formed the FAS.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Observable Focal-onset Seizure Frequency From Baseline Over the 12 Week Maintenance Period</title>
          <description>During the study, participants kept diaries to record daily seizure activity. The percentage of participants who experienced a 50 % or greater reduction in seizure frequency per 28 days relative to Baseline (responders) was assessed.</description>
          <population>The Full Analysis Set (FAS) consisted of all study participants in the RS who were administered at least 1 dose or a partial dose of IMP and had Baseline and at least 1 post-Baseline seizure frequency data during the 16-week Treatment Period.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="81"/>
                <count group_id="O5" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.49" spread="58.26"/>
                    <measurement group_id="O2" value="24.70" spread="46.62"/>
                    <measurement group_id="O3" value="25.25" spread="51.73"/>
                    <measurement group_id="O4" value="20.79" spread="66.54"/>
                    <measurement group_id="O5" value="15.79" spread="67.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dose group comparisons to Placebo p-value were based on the Wilcoxon-Mann-Whitney test. The Hodges-Lehmann nonparametric estimator was used to estimate the median difference between each PSL dose group versus placebo, along with the corresponding 95% CI of the estimate.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>=0.316</p_value>
            <p_value_desc>Nominal p-values were not adjusted for multiplicity.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>7.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.59</ci_lower_limit>
            <ci_upper_limit>21.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Dose group comparisons to Placebo p-value were based on the Wilcoxon-Mann-Whitney test. The Hodges-Lehmann nonparametric estimator was used to estimate the median difference between each PSL dose group versus placebo, along with the corresponding 95% CI of the estimate.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>=0.133</p_value>
            <p_value_desc>Nominal p-values were not adjusted for multiplicity.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>9.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.15</ci_lower_limit>
            <ci_upper_limit>23.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Dose group comparisons to Placebo p-value were based on the Wilcoxon-Mann-Whitney test. The Hodges-Lehmann nonparametric estimator was used to estimate the median difference between each PSL dose group versus placebo, along with the corresponding 95% CI of the estimate.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>=0.203</p_value>
            <p_value_desc>Nominal p-values were not adjusted for multiplicity.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>8.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.95</ci_lower_limit>
            <ci_upper_limit>21.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Dose group comparisons to Placebo p-value were based on the Wilcoxon-Mann-Whitney test. The Hodges-Lehmann nonparametric estimator was used to estimate the median difference between each PSL dose group versus placebo, along with the corresponding 95% CI of the estimate.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>=0.784</p_value>
            <p_value_desc>Nominal p-values were not adjusted for multiplicity.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>2.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.65</ci_lower_limit>
            <ci_upper_limit>17.79</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent AEs were collected from Baseline to Safety Follow-Up (up to Week 23)</time_frame>
      <desc>Adverse events refer to the SS which consisted of all participants who were administered at least 1 dose or a partial dose of IMP.&#xD;
TEAEs counts are for each study period: Treatment Period, Conversion Period for participants who entered the OLE study and Taper Period followed by SFU for participants not entering OLE study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo Treatment Period (SS)</title>
          <description>Participants randomized to the placebo group received 5-6 placebo tablets to maintain the blinding up to week 19. Participants formed the Safety Set (SS).</description>
        </group>
        <group group_id="E2">
          <title>Padsevonil 50mg BID Treatment Period (SS)</title>
          <description>Participants were randomized to receive a combination of tablets of padsevonil 50 mg and placebo (as appropriate) to maintain the blinding, bid up to week 19. Participants formed the SS.</description>
        </group>
        <group group_id="E3">
          <title>Padsevonil 100mg BID Treatment Period (SS)</title>
          <description>Participants were randomized to receive a combination of tablets of padsevonil 100 mg and placebo (as appropriate) to maintain the blinding, bid up to week 19. Participants formed the SS.</description>
        </group>
        <group group_id="E4">
          <title>Padsevonil 200mg BID Treatment Period (SS)</title>
          <description>Participants were randomized to receive a combination of tablets of padsevonil 200 mg and placebo (as appropriate) to maintain the blinding, bid up to week 19. Participants formed the SS.</description>
        </group>
        <group group_id="E5">
          <title>Padsevonil 400mg BID Treatment Period (SS)</title>
          <description>Participants were randomized to receive a combination of tablets of padsevonil 400 mg and placebo (as appropriate) to maintain the blinding, bid up to week 19. Participants formed the SS.</description>
        </group>
        <group group_id="E6">
          <title>Placebo Conversion Period (SS)</title>
          <description>A 3-week Conversion Period was required for study participants who chose to enroll in the open-label extension (OLE) study at the end of the 12-week Maintenance Period. Participants initially randomized to placebo progressively received padsevonil in a blinded way to reach the entry dose of 400mg/day for the OLE. Participants formed the Safety Set (SS).</description>
        </group>
        <group group_id="E7">
          <title>Padsevonil 50mg BID Conversion Period (SS)</title>
          <description>A 3-week Conversion Period was required for study participants who chose to enroll in the OLE study at the end of the 12-week Maintenance Period. The dose for participants initially randomized to padsevonil 50mg bid was gradually adapted (increased or decreased) in a blinded way to reach the entry dose of 400mg/day for the OLE. Participants formed the SS.</description>
        </group>
        <group group_id="E8">
          <title>Padsevonil 100mg BID Conversion Period (SS)</title>
          <description>A 3-week Conversion Period was required for study participants who chose to enroll in the OLE study at the end of the 12-week Maintenance Period. The dose for participants initially randomized to padsevonil 100mg bid was gradually adapted (increased or decreased) in a blinded way to reach the entry dose of 400mg/day for the OLE. Participants formed the SS.</description>
        </group>
        <group group_id="E9">
          <title>Padsevonil 200mg BID Conversion Period (SS)</title>
          <description>A 3-week Conversion Period was required for study participants who chose to enroll in the OLE study at the end of the 12-week Maintenance Period. The dose for participants initially randomized to padsevonil 200mg bid was gradually adapted (increased or decreased) in a blinded way to reach the entry dose of 400mg/day for the OLE. Participants formed the SS.</description>
        </group>
        <group group_id="E10">
          <title>Padsevonil 400mg BID Conversion Period (SS)</title>
          <description>A 3-week Conversion Period was required for study participants who chose to enroll in the OLE study at the end of the 12-week Maintenance Period. The dose for participants initially randomized to padsevonil 400mg bid was gradually adapted (increased or decreased) in a blinded way to reach the entry dose of 400mg/day for the OLE. Participants formed the SS.</description>
        </group>
        <group group_id="E11">
          <title>Placebo Taper and SFU Period (SS)</title>
          <description>A 4-week Taper Period was required for participants who chose not to enroll in the OLE study or who discontinued prior to the end of the 12-week Maintenance Period. Participants initially randomized to placebo group received 5-6 placebo tablets to maintain the blinding and have been gradually tapered off the IMP over a 3-week period followed by 1-week drug-free period.&#xD;
Afterwards, participants had a Safety Follow-Up visit 30 days after the last IMP intake. Participants formed the Safety Set (SS).</description>
        </group>
        <group group_id="E12">
          <title>Padsevonil 50mg BID Taper and SFU Period (SS)</title>
          <description>A 4-week Taper Period was required for participants who chose not to enroll in the OLE study or who discontinued prior to the end of the 12-week Maintenance Period. Participants initially randomized to padsevonil 50 mg bid have been gradually tapered off the IMP over a 3-week period followed by 1-week drug-free period. Afterwards, participants had a Safety Follow-Up visit 30 days after the last IMP intake. Participants formed the SS.</description>
        </group>
        <group group_id="E13">
          <title>Padsevonil 100mg BID Taper and SFU Period (SS)</title>
          <description>A 4-week Taper Period was required for participants who chose not to enroll in the OLE study or who discontinued prior to the end of the 12-week Maintenance Period. Participants initially randomized to padsevonil 100 mg bid have been gradually tapered off the IMP over a 3-week period followed by 1-week drug-free period. Afterwards, participants had a Safety Follow-Up visit 30 days after the last IMP intake. Participants formed the SS.</description>
        </group>
        <group group_id="E14">
          <title>Padsevonil 200mg BID Taper and SFU Period (SS)</title>
          <description>A 4-week Taper Period was required for participants who chose not to enroll in the OLE study or who discontinued prior to the end of the 12-week Maintenance Period. Participants initially randomized to padsevonil 200 mg bid have been gradually tapered off the IMP over a 3-week period followed by 1-week drug-free period. Afterwards, participants had a Safety Follow-Up visit 30 days after the last IMP intake. Participants formed the SS.</description>
        </group>
        <group group_id="E15">
          <title>Padsevonil 400mg BID Taper and SFU Period (SS)</title>
          <description>A 4-week Taper Period was required for participants who chose not to enroll in the OLE study or who discontinued prior to the end of the 12-week Maintenance Period. Participants initially randomized to padsevonil 400 mg bid have been gradually tapered off the IMP over a 3-week period followed by 1-week drug-free period. Afterwards, participants had a Safety Follow-Up visit 30 days after the last IMP intake. Participants formed the SS.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA22.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Traumatic haemothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Focal dyscognitive seizures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Seizure cluster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Acute psychosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Medical device battery replacement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA22.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="60" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="53" subjects_at_risk="82"/>
                <counts group_id="E5" subjects_affected="65" subjects_at_risk="81"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="18" subjects_at_risk="64"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="66"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="57"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E15" subjects_affected="4" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="83"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="81"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="83"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="81"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="83"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E5" events="13" subjects_affected="7" subjects_at_risk="81"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="81"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E4" events="7" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="81"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="83"/>
                <counts group_id="E2" events="27" subjects_affected="20" subjects_at_risk="81"/>
                <counts group_id="E3" events="17" subjects_affected="12" subjects_at_risk="83"/>
                <counts group_id="E4" events="22" subjects_affected="14" subjects_at_risk="82"/>
                <counts group_id="E5" events="21" subjects_affected="20" subjects_at_risk="81"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" events="2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="83"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E3" events="13" subjects_affected="9" subjects_at_risk="83"/>
                <counts group_id="E4" events="11" subjects_affected="7" subjects_at_risk="82"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="83"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Anticonvulsant drug level increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="83"/>
                <counts group_id="E2" events="19" subjects_affected="18" subjects_at_risk="81"/>
                <counts group_id="E3" events="31" subjects_affected="23" subjects_at_risk="83"/>
                <counts group_id="E4" events="25" subjects_affected="19" subjects_at_risk="82"/>
                <counts group_id="E5" events="55" subjects_affected="28" subjects_at_risk="81"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E10" events="6" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="83"/>
                <counts group_id="E2" events="24" subjects_affected="19" subjects_at_risk="81"/>
                <counts group_id="E3" events="29" subjects_affected="24" subjects_at_risk="83"/>
                <counts group_id="E4" events="26" subjects_affected="25" subjects_at_risk="82"/>
                <counts group_id="E5" events="35" subjects_affected="30" subjects_at_risk="81"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E7" events="5" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="83"/>
                <counts group_id="E2" events="29" subjects_affected="17" subjects_at_risk="81"/>
                <counts group_id="E3" events="16" subjects_affected="9" subjects_at_risk="83"/>
                <counts group_id="E4" events="21" subjects_affected="15" subjects_at_risk="82"/>
                <counts group_id="E5" events="31" subjects_affected="9" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E8" events="3" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" events="5" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" events="9" subjects_affected="8" subjects_at_risk="82"/>
                <counts group_id="E5" events="14" subjects_affected="14" subjects_at_risk="81"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="82"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Nystagmus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="83"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="81"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="83"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" events="6" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" events="9" subjects_affected="7" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Paranoia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>UCB</name_or_title>
      <organization>Cares</organization>
      <phone>+1844 599 ext 2273</phone>
      <email>UCBCares@ucb.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

